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ABSTRACT  
Objective: To investigate the effects of berberine chloride and hyperthermia on the expression of Osterix 
(Osx), Runt-related transcription factor 2 (RUNX-2), receptor activator of nuclear factor kappa-B ligand 
(RANKL), cyclin-dependent kinase 2 (CDK2), CDK4, interleukin (IL)-6 and IL-11 genes. 
Methods: Osteosarcoma cells (MG-63 cells) were treated with three different hyperthermia conditions for 
1 h: two groups with mild, two with moderate and two with severe hyperthermia (at 39, 43 and 45 °C, re-
spectively). Berberine chloride (80 µg/ ml) was used for treating one group of mild, moderate and severe 
hyperthermia (combination). All treated groups were recovered at 37°C for 24 h. Another exposure to hy-
perthermia (1 h) and recovery at 37°C for 3 h were applied. Gene expression levels were then determined 
using RT2 PCR profiler arrays. 
Results: The expression of Osx was highly upregulated in all groups except in the groups treated with se-
vere hyperthermia and mild hyperthermia in combination with berberine chloride. Mild hyperthermia 
alone induced a slight increase in the expression of RUNX2, whereas severe hyperthermia significantly 
suppressed RUNX2 levels. Berberine alone significantly induces the up-regulation of RANKL expression. 
On the other hand, CDK2 mRNA was downregulated in all groups. CDK4 was equally regulated in mild hy-
perthermia compared to the control group. However, the expression was significantly downregulated in 
other groups, especially in severe hyperthermia. IL-6 was significantly upregulated in berberine group and 
all groups of combinations, whereas mild and moderate hyperthermia significantly induced the expression 
of IL-11 mRNA. 
Conclusions: Hyperthermia and berberine chloride can promote osteosarcoma cells differentiation and 
suppresses cell cycle genes. 
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1. Introduction  
Osteoblasts and osteosarcoma cells originate 
from mesenchymal stem cells. Although osteo-
blasts undergo multiple differentiation steps, 
the differentiation of osteosarcoma cells is im-
paired so that they remain as immature osteo-
blast-like cells (1). Osterix (Osx) and Runt-
related transcription factor 2 (RUNX2) are os-
teoblast-specific transcription factors necessary 
for the differentiation of osteoblasts and bone 
formation. Stein et al. (2) concluded that RUNX2 
has a dual function in osteoblast proliferation 
and differentiation. It enhances their matura-
tion by supporting the exit from the cell cycle 
and attenuation of osteoblast growth and acti-
vates the genes of osteoblast maturation to 
promote bone cell phenotype development and 
lineage commitment (2). RUNX2 induces BAX 
expression and increases the sensitivity of sar-
coma osteogenic (Saos2) cell lines to apoptosis 
(3). Inversely, Martin et al. (4) found overex-
pression of RUNX2 mRNA in patients with oste-
osarcoma, leading to a poor response to chemo-
therapy compared to the good response in pa-
tients with other types of tumors. Osx is an im-
portant osteoblast-specific transcription factor 
that plays an essential role in osteoblast prolif-
eration and differentiation (1, 5). It binds to 
substance P (Sp)-binding sites on gene promot-
ers to regulate their expression. According to 
Cao et al. (6), Osx transcript decreased in three 
human and two mouse osteosarcoma cell lines 
compared to normal cell lines. Moreover, trans-
fection of a mouse osteosarcoma cell line with 
the Osx gene resulted in the inhibition of tumor 
incidence, growth and volume (6). 
Osteoclasts are cells derived from the mon-
ocyte/macrophage lineage and play an im-
portant role in bone metabolism through their 
engagement in the bone resorption process. The 
tumor necrosis factor (TNF) family consists of 
several ligand-receptor proteins that play a role 
in several cellular processes including apopto-
sis, homeostasis and development (7). One of 
such proteins is the receptor activator of nucle-
ar factor kappa-B ligand (RANKL), which is very 
important for the activation, formation, and 
function of osteoclasts (8). RANKL is expressed 
and synthesized by different types of cells such 
as osteoblasts and bone marrow stromal cells 
(8). On the other hand, RANK, the receptor for 
RANKL, is another member of the TNF family, 
which is mainly expressed on the cells of the 
monocyte/macrophage lineage such osteoclasts 
and pre-osteoclasts (7). The RANKL/ RANK in-
teraction is essential for osteoclastogenesis as it 
stimulates the differentiation and maturation of 
osteoclasts (9). RANK expression is regulated 
by TNF-α, parathyroid hormone-related pro-
tein, transforming growth factor-α, interleukins 
(IL-1, IL-6 and IL-8) (10). Activated osteoclasts 
attach to the bone and release various proteas-
es, which facilitate the resorption of the non-
mineralized constituents of bone (11).  
Berberine is a quaternary ammonium salt 
that belongs to the family of isoquinoline alka-
loids. It is found in several plant species such as 
Berberis aristata, Hydrastis canadensis (golden-
seal) and Coptis chinensis (12). Several studies 
have shown the anticancer properties of berber-
ine against different types of cancers, including 
leukemia, osteosarcoma and colon cancer (13–
15). On the other hand, hyperthermia (39–45°C) 
has been shown to be a powerful enhancer for 
chemo- and radiotherapies through the elimina-
tion of treatment-resistant tumor cells (16).  
Mantena et al. (17) reported that treatment 
of human prostate cancer cells with berberine 
led to G1-phase arrest with suppression of cy-
clin-dependent kinase (CDK) 2, CDK4, and CDK6 
proteins. Additionally, a recent study showed 
that berberine alone or in combination with 
doxorubicin led to G2/M arrest in human breast 
cancer cells (18). However, published data on 
the effects of berberine chloride, hyperthermia 
or their combination on osteogenesis and tumor 
cell differentiation are still very scarce. There-
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fore, the present study aimed to investigate the 
effects of berberine chloride and various heat 
conditions on the gene expression of Osx, 
RUNX-2, RANKL, cyclin-dependent kinase 2 
(CDK2), CDK4, IL-6 and IL-11. 
2. Methods 
2.1. Cell culture 
Human MG-63 Osteoblast-like osteosarcoma 
cells were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA, USA) 
and cultured in Dulbecco's modified Eagle me-
dium: nutrient mixture F-12 (DMEM/F-12) with 
10% fetal bovine serum and 1% streptomycin 
and penicillin (Life Technologies, Grand Island, 
NY, USA). Culture media were changed every 48 
h. The cells were sub-cultured in an atmosphere 
of 5% CO2 at 37°C overnight and then trans-
ferred to a different incubator with the required 
pre-adjusted temperature. 
 
2.2. Hyperthermia treatment and berberine chlo-
ride 
Six groups of MG-63 cells were treated with hy-
perthermia for 1 h: two with mild, two with 
moderate and two with severe hyperthermia (at 
39, 43 and 45°C, respectively). After treating the 
cells with hyperthermia, a low dose of berber-
ine chloride (80 µg/ ml) was used for treating 
one group of mild, moderate and severe hyper-
thermia (combination). Then, all treated groups 
were recovered at 37°C for 24 h, and all groups 
were treated with hyperthermia (at 39, 43 and 
45°C) for a second time (1 h) and were recov-
ered at 37°C for 3 h.  
2.3. PCR gene expression arrays (RT2 PCR profiler 
arrays) 
The RNeasy Mini Kit with on-column DNase 
treatment step (Qiagen, Hilden, Germany) was 
used for RNA extraction. Genomic DNA was 
eliminated by mixing 2 µl of DNA elimination 
buffer (Qiagen, Germany) with 1-8 µl of total 
RNA. The mixture was incubated at 42°C for 10 
min. For cDNA synthesis, the RT2 First Strand 
Kit (Qiagen, Hilden, Germany) was used. Each 
reaction contained 1µg of DNA-free RNA (10 µl), 
l µl primers solution and external control mix, 4 
µl 5x RT buffer, 3 µl dH2O and 2 µl RT enzyme 
mix (Qiagen, Hilden, Germany). This mixture 
was incubated in a Mastercycler Gradient ma-
chine (Eppendorf, Hamburg, Germany) at 42°C 
for 15 min. and the reaction was terminated by 
increasing the temperature to 95°C for 5 min. 
Prior to running the PCR array, 91 µl of distilled 
H2O was added to the cDNA and mixed gently. 
A microliter of the cDNA product was load-
ed into each well of the RT2 profiler PCR array 
after mixing with RT2 PCR Master Mix (25 µl) 
(Qiagen, Hilden, Germany) and amplified using 
the iQ™ 5 Real-Time PCR Detection System (Bio-
Rad, USA). Three biological replicates were in-
vestigated for each group. The expression levels 
of Osx, RUNX-2, CDK2, CDK4, IL-6, IL-11 and 
RANKL were determined. Gene expression was 
normalized to the expression of glyceraldehyde 
3-phosphate dehydrogenase gene (GAPDH; cat-
alog number: PPH00150) and hypoxanthine 
phosphoribosyltransferase 1 gene (HPRT1; cat-
alog number: PPH01018) as reference genes us-
ing the RT2 profiler PCR arrays. 
2.4. Statistical analysis 
Data were analyzed using Student’s t-test to com-
pare every treated group to control by using a 
web-based SABioscience RT2 Profiler PCR Array 
Data Analysis 
(http://pcrdataanalysis.sabiosciences.com/ 
pcr/arrayanalysis.php). Differences were consid-
ered statistically significant at P values < 0.05. 
3. Results 
Figure (1) shows the effect of hyperthermia and 
berberine chloride on the expression of RUNX2, 
RANKL and Osx genes. Mild hyperthermia in-
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duced a slight increase in the expression of 
RUNX2 mRNA, whereas severe hyperthermia 
significantly suppressed the levels of expres-
sion. Moderate hyperthermia alone and mild 
hyperthermia alone or in combination with 
berberine increased gene expression compared 
to the control. Additionally, berberine chloride 
alone was more effective in increasing RANKL 
expression. Furthermore, the combination of 
berberine with mild hyperthermia attenuated 
the inducing effect of berberine chloride. Ex-
pression of Osx was highly induced in all 
groups, except for the combination groups of 
severe hyperthermia and mild hyperthermia 
plus berberine chloride. 
 
Figure 1. Effect of hyperthermia, berberine chloride and their combination on gene expression of RUNX2, RANKL and Osx 
 
Figure (2) shows the long-term effect of 
berberine chloride, hyperthermia and their 
combination on the expression of cell cycle 
genes. CDK2 mRNA was downregulated in all 
groups. CDK4 mRNA was equally regulated in 
mild hyperthermia compared to the control 
group. However, the expression was downregu-
lated in other groups, especially in the severe 
hyperthermia group (P <0.5). 
 
 
Figure 2. Effect of hyperthermia, berberine chloride and their combination on gene expression of CDK2 and CDK4 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
37°C 37°C+ Ber 39°C 39°C+Ber 43°C 43°C+Ber 45°C 45°C+Ber
CDK2
CDK4
*
*
F
o
ld
  
c
h
a
n
g
e
Nashiry et al., Yemeni J Med Sci 2018; 37-43  
https://doi.org/10.20428/YJMS.12.1.A5 
 
 
© 2018 University of Science and Technology, Sana'a, Yemen. This article can be unrestrictedly used, distributed or reproduced 
in any medium, provided that credit is given to the authors and the journal.  
41 
IL-6 was highly upregulated, with statistical-
ly significant differences in the berberine chlo-
ride group and all combination groups (hyper-
thermia + berberine chloride). Mild and moder-
ate hyperthermia significantly induced the ex-
pression of IL-11 mRNA. However, such induc-
tion was attenuated after combination with ber-
berine chloride, which resulted in a significant 
downregulation with mild hyperthermia and re-
turning to the basic level with moderate hyper-
thermia (Figure 3). 
 
Figure 3. Effects of hyperthermia, berberine chloride and their combination on gene expression of IL-6 and IL-11 
 
4. Discussion 
In the present study, berberine chloride led to 
the suppression of CDK2 and CDK4 mRNA ex-
pression. This finding is in agreement with a 
previous study that showed G1-phase arrest 
with suppression of CDK2, CDK4 and CDK6 pro-
teins in human prostate cancer cells exposed to 
berberine chloride (17). Additionally, a recent 
study showed that berberine alone or in combi-
nation with doxorubicin led to G2/M arrest in 
human breast cancer cells (18). 
In the present study, severe hyperthermia 
alone significantly suppressed RUNX2 expres-
sion, which declined to near normal levels of 
control after combination with berberine. It is 
worth mentioning that thermal stress induces 
the expression of alkaline phosphatase, RUNX2 
and Osx in mouse osteoblast MC3T3-E1 cells 
(19). Osx was upregulated in all groups. Overall, 
the present study showed that hyperthermia 
may induce differentiation of osteosarcoma 
cells. Kajiya et al. (19) reported that photo-
thermal stress promotes mineral deposition in 
enhanced tooth-extracted sockets. On the other 
hand, it has been reported that berberine acti-
vates RUNX2 by p38 mitogen-activated protein 
kinase, leading to increased expression of oste-
ogenic marker genes involving osteocalcin and 
osteopontin (20). In the present study, berber-
ine-induced upregulated levels of Osx are con-
sistent with the findings by Lee et al. (20) in 
normal osteoblasts. 
RANKL is important for osteoclastogenesis 
(21), where both RANKL and osteoclastogenesis 
were found to be downregulated by berberine 
(22). Therefore, berberine has been suggested 
to be useful in the prevention of osteoporosis 
(22). It is noteworthy that increased osteoclastic 
activity in osteosarcoma is a sign of increased 
tumor cell invasion (11). This could explain the 
inhibitory effect of berberine on osteoclast for-
mation in osteosarcoma and, therefore, its pro-
tective action against cancer cell invasion. 
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In the present study, severe hyperthermia 
suppressed RANKL expression, whereas berber-
ine, mild hyperthermia and the combination of 
mild hyperthermia with berberine and moder-
ate hyperthermia upregulated RANKL expres-
sion by more than twofold. This is in contrast to 
a finding by Zhou et al. (22), where berberine in 
normal osteoblasts reduced RANKL expression. 
Xue et al. (23) also showed suppression of oste-
oclast differentiation in a co-culture model sys-
tem. Suppression of RANKL has been suggested 
as a good strategy for the treatment of aggres-
sive osteosarcomas (24). Although berberine in-
creased RANKL expression in osteosarcoma 
cells when given alone, it did not attenuate the 
effect of severe hyperthermia on RANKL expres-
sion, and therefore, had probably no negative ef-
fect on the treatment of osteosarcoma with hy-
perthermia. However, this requires further in-
depth molecular studies because berberine sig-
nificantly increased the expression of IL-6 and 
IL11, regardless of being given alone or in com-
bination with hyperthermia. It is noteworthy 
that IL-6 and IL-11 are strongly involved in the 
upregulation of RANKL, and consequently, in os-
teoclastogenesis (11).  
This study was conducted on one cell line 
with a single dose of berberine chloride, and no 
protein expression assays were performed due 
to the time and budget shortages. Thus, further 
studies are recommended to investigate the re-
sponse of more osteosarcoma cell line types to 
the combined effects of berberine chloride and 
hyperthermia. 
 
5. Conclusions 
Berberine chloride suppresses cell cycle genes 
when used alone and in combination with mild 
or moderate hyperthermia. In addition, it induc-
es Osx expression when used alone or in combi-
nation. Therefore, berberine chloride and hyper-
thermia could be effectively used in promoting 
osteosarcoma differentiation and, therefore, 
help in the treatment of osteosarcoma. 
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